MedTrace Logo

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9541

Last updated 2024-06-04

No results posted yet for this study

Summary

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.

Conditions

Interventions

DRUG

Obicetrapib

10mg obicetrapib tablet

DRUG

Placebo

Placebo tablet to resemble obicetrapib

Sponsors & Collaborators

Principal Investigators

  • Marc Ditmarsch, MD · NewAmsterdam Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2026-11-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • China
  • Croatia
  • Czechia
  • Denmark
  • Finland
  • Georgia
  • Germany
  • Hungary
  • Israel
  • Italy
  • Japan
  • Jordan
  • Latvia
  • Netherlands
  • Poland
  • Slovakia
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05202509 on ClinicalTrials.gov